| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to molecular biology, biotechnology, medicine and aims at the prevention and treatment of rotaviral infection. What is presented is a rotavirus infection vaccine based on the hybrid protein characterised by sequences SEQ ID NO.: l, SEQ ID NO.: 2, consisting of immunogenic epitopes of flexible bridged VP6 and VP8 proteins (versions). What is presented is the rotavirus infection vaccine based on the hybrid protein (SEQ ID NO.: 3 - SEQ ID NO.: 6) consisting of immunogenic epitopes of flexible bridged VP6 and VP8 proteins and an adjuvant, flagellin fragments (versions). The hybrid protein, an active component of the versions of the vaccine is produced in procaryote and eucaryote cells with the use of recombinant DNA technology and various purification procedures. The immunological polyvalence of the presented versions of the rotavirus A, B and C vaccine, and also the preventive and therapeutic action have been shown.EFFECT: using the given versions of the vaccine enables providing the general protection of the individual against rotaviruses.7 cl, 6 dwg, 1 tbl, 9 ex |
